Genentech's Covid-fighting drug in short supply just two months after FDA greenlight
Plateauing vaccination rates and a surge of Covid infections has left Covid patients, rheumatoid arthritis patients and some cancer patients competing for a dwindling supply of the drug.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Arthritis | Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Rheumatoid Arthritis | Rheumatology | Vaccines